company - ISA Therapeutics BV
The Company has built a proprietary immunotherapy platform based on its Synthetic Long Peptide (SLP®) concept and its AMPLIVANT® technology.
This company is:
Verified
Prof. Cornelis Melief to Present Novel AMPLIVANT™ Platform at AACR Annual Meeting 2013 - ISA Therapeutics BV
Leiden, The Netherlands, April 2, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., will present details on the novel AMPLIVANT™ platform at this year’s American Association for Cancer Research (AACR) Annual Meeting. AMPLIVANT™ is based on a powerful, proprietary toll-like receptor (TLR) ligand improving immunotherapies. Presentation title: “Synthetic vaccine for immunotherapy of high risk HPV infections“ Symposium: SY27 “New Cancer Vaccines“ Abstract number: SY27-01 Date: April 9, 2013, at 10:40 a.m. Location: Room 202 at the Washington Convention Center. The abstract is available at the AACR
Verified
technology - ISA Therapeutics BV
ISA Pharmaceuticals is pioneering the development of SLP as targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections.
Verified
ISA Pharmaceuticals’ Lead Product ISA101 Efficiently Engages the Immune System Against Virus-Induced Pre-malignant and Malignant Lesions - ISA Therapeutics BV
– ISA101 clinically effective against HPV-induced vulvar / vaginal lesions and cervical cancer – Optimum immunotherapy window in cancer identified Leiden, The Netherlands, April 14, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has announced the publication of two peer-reviewed research manuscripts demonstrating the clinical efficacy of its lead product ISA101 in treating high-grade vulvar intraepithelial neoplasia (VIN), and synergy with chemotherapy in cervical cancer. In cervical cancer, the optimum window for treatment with ISA101 starts two weeks after the second chemotherapy cycle has been completed. The multi-center research was conducted in close collaboration with Leiden University Medical Center (LUMC). Publications
View all products
Keywords
Industries
White&Case Archives - ISA Therapeutics BV
ISA Pharmaceuticals to present at the Virtual 6th Solebury Trout Summer 2020 Private Company Showcase
Where is ISA Pharmaceuticals located?
The company ISA Pharmaceuticals is located in Leiden, South Holland, Netherlands. It's worth noting that the company may has more corporate locations
How many employees does ISA Pharmaceuticals approximately have?
As of the latest available information ISA Pharmaceuticals has around 11-50 employees worldwide.
When was ISA Pharmaceuticals founded?
ISA Pharmaceuticals was founded in 2004
In which industries does ISA Pharmaceuticals mainly work?
The company ISA Pharmaceuticals has it's main focus in the industries of Biotechnology
Flow Pharma
United States
1-10 Employees
1999
Elicio Therapeutics
United States
11-50 Employees
2011
Amal Therapeutics
Switzerland
11-50 Employees
2012
Geneos Therapeutics
United States
1-10 Employees
2016
Immunovative Therapies Ltd.
Israel
11-50 Employees
2004
Immunomic Therapeutics
United States
11-50 Employees
2005
BioVaxys
United States
1-10 Employees
2018
NantKwest
United States
51-100 Employees
2002
Topics which have been searched by others and may be interesting for you:
